Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Lauren Biscaldi is the managing editor of Drug Topics

Articles

A presentation at the National Community Pharmacists Association Annual Meeting and Exposition focused on the latest on vaccines for flu and respiratory syncytial virus (RSV).


Key Flu and RSV Recommendations for the 2024-2025 Respiratory Virus Season

As with other disease states, biomarkers that can provide value across diagnosis, prognosis, and treatment response, have been heavily sought out to help guide optimal treatment decisions throughout the course of disease.

Researchers Outline Promising Biomarkers Throughout Course of MS

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Social isolation significantly increases the risk of mortality in patients with chronic obstructive pulmonary disease (COPD), highlighting the need for targeted interventions to address this issue.

Social Isolation Linked to Increased Mortality in Patients With COPD

Attendees of the centennial American Heart Association (AHA) conference commend the meeting's ability to bring together diverse, interdisciplinary perspectives from across the globe. 

Shaping the Future of Cardiology: Key Takeaways From AHA 2024

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Redefining Menopause Management: Addressing Gaps, Embracing Innovations, and Enhancing Outcomes 

Closing Thoughts: Evolving Treatment Paradigms in Menopause Management

Videos

Panelists discuss how innovative neurokinin-targeted therapies for vasomotor symptoms can reshape menopause management and address unmet needs and improving patient outcomes while highlighting the importance of equity in treatment access.

Understanding the Burden of Menopausal Vasomotor Symptoms

Panelists discuss how underlying factors, including patient resistance to conventional treatments and the stigma surrounding menopause, contribute to the persistent undertreatment of vasomotor symptoms (VMS), which can severely impact women’s quality of life and increase their risk for long-term health issues such as cardiovascular disease and Alzheimer disease.

Barriers to VMS Treatment and Impact on Long-Term Health

Panelists discuss how to improve treatment rates for vasomotor symptoms (VMS) by identifying actionable steps, examining the influence of socioeconomic status on health care access, and proposing initiatives to ensure equitable care for all women experiencing menopause.

Improving Access and Equity in VMS Treatment

Panelists discuss how to effectively integrate vasomotor symptom (VMS) treatment into comprehensive health management plans for women, taking into account the significant comorbidities associated with menopause, such as cardiovascular disease and osteoporosis.

Integrating VMS Treatment Into Comprehensive Women’s Health Management

Panelists discuss the role of neurokinin in the pathophysiology of vasomotor symptoms (VMS) and examine the mechanisms of action of novel nonhormonal agents such as fezolinetant and elinzanetant, highlighting the advantages of targeting neurokinin pathways over traditional hormonal treatments and their potential to address related menopause issues such as mood disturbances and sleep disorders.

Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

Panelists discuss the methodologies of the SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 trials that supported the approval of fezolinetant for moderate to severe vasomotor symptoms (VMS) and examine the key safety and efficacy results derived from these studies.

Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

Panelists discuss the methodologies of the OASIS 1, 2, and 3 trials that investigated elinzanetant, highlighting key findings regarding its efficacy in reducing the frequency and severity of vasomotor symptoms (VMS) compared with other treatments, as well as its impact on quality of life and the speed at which patients experienced symptom improvement.

Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

Panelists discuss the notable adverse events observed in the OASIS trials with elinzanetant and compare the safety profiles of elinzanetant and fezolinetant with those of traditional treatments for vasomotor symptoms (VMS).

Safety Profiles of Neurokinin-Targeted Therapies for VMS

Panelists discuss the importance of addressing sleep disturbances in menopause management, even in the absence of vasomotor symptoms (VMS), and explore how emerging research on elinzanetant could impact sleep quality and its links to mood disorders, cardiovascular disease, and Alzheimer disease, while also contemplating the potential shift in the treatment paradigm for VMS with the introduction of new neurokinin-targeted therapies as either standard of care or in combination with other treatments.

Beyond Hot Flashes: The Importance of Sleep in Menopause Management

Panelists express their gratitude for the informative discussion and share their final thoughts on the evolving landscape of menopause management and the potential impact of new therapies on improving patient outcomes.

I'm sorry, it seems that there is no article text provided for me to summarize and analyze. Please provide the text of the article, and I'll be happy to assist you

Closing Thoughts: Evolving Treatment Paradigms in Menopause Management

EP: 1.Understanding the Burden of Menopausal Vasomotor Symptoms

EP: 2.Barriers to VMS Treatment and Impact on Long-Term Health

EP: 3.Improving Access and Equity in VMS Treatment

EP: 4.Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP: 5.Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP: 6.Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

EP: 7.Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

EP: 8.Safety Profiles of Neurokinin-Targeted Therapies for VMS

EP: 9.Beyond Hot Flashes: The Importance of Sleep in Menopause Management

EP: 10.Closing Thoughts: Evolving Treatment Paradigms in Menopause Management